Effect of GLP-1 on Insulin Biosynthesis and Turnover Rates

Phase 1

Terminated

• Conditions: Type 2 Diabetes
• Interventions: Drug: glucagon like peptide-1; Dietary Supplement: glucose control

• Registration Number: NCT00609154
• Lead Sponsor: Albert Einstein College of Medicine

Brief Summary

The gut hormone glucagon like peptide-1 (GLP-1) has been shown to have important effects on maintaining the function and health of the insulin producing beta cells. This hormone is known to increase the production rate of new insulin as well as increase the release of insulin into the blood.

Detailed Description

We will measure the rate of new insulin production in subjects with Type 2 diabetes compared to non diabetic subjects. We hypothesize that subjects with Type 2 diabetes make less insulin in response to GLP-1 compared to non diabetic subjects.

Study Timeline

• Study First Submitted: 2008-01-23
• Study First Submitted QC: 2008-02-05
• Study First Posted: 2008-02-06
• Study Start: 2010-08-12
• Primary Completion: 2014-05-13
• Study Completion: 2014-05-13
• Results First Submitted: 2023-12-22
• Status Verified: 2024-02
• Results First Submitted QC: 2024-02-05
• Last Update Submitted: 2024-02-05
• Results First Posted: 2024-02-28
• Last Update Posted: 2024-02-28

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Type 2 Diabetes
• Non diabetic

Exclusion Criteria

• Currently taking medication such as thiazolidinediones, metformin, Exenatide, or sitagliptin
• Chronic condition such as chronic heart failure CHF), Coronary Artery Disease (CAD), or chronic renal failure (CRF)
• Anemia

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Diabetic Group	glucagon like peptide-1	Participants with Type 2 diabetes
Diabetic Group	glucose control	Participants with Type 2 diabetes
Non-diabetic Group	glucagon like peptide-1	Participants who are non-diabetic will serve as control. treatment is matched to experimental group
Non-diabetic Group	glucose control	Participants who are non-diabetic will serve as control. treatment is matched to experimental group

Primary Outcome Measures

Name	Time	Method
Insulin Biosynthesis Rate	24 hours	Blood insulin biosynthesis rate

Trial Locations

Locations (1)

Albert Einstein College of Medicinie; 🇺🇸 Bronx, New York, United States